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We recently took a preclinical approach and investi-
gated this issue using a well-established preclinical an-
imal model of antipsychotics-conditioned avoidance re-
sponse (CAR) model (Li et al., 2007, 2009; Mead and Li, 
in press). All currently available antipsychotics, at clin-
ically relevant doses, selectively disrupt avoidance re-
sponding to a conditional stimulus (CS, e.g. white noise) 
without altering escape responding to an unconditional 
stimulus (US, e.g. footshock) (Arnt, 1982; Wadenberg et 
al., 2001; Natesan et al., 2006). Thus, an antiavoidance re-
sponding effect is frequently used as a validated behav-
ioral index of ‘antipsychotic’ property. Using this model, 
we found that rats treated with haloperidol (HAL), ris-
peridone (RIS) and olanzapine (OLZ) daily for 7 consec-
utive days showed a progressive across-session decline 
in avoidance responding, suggesting that antipsychot-
ics may progressively attenuate the motivational salience 
of the CS (Wise, 2004; Li et al., 2009). We also found that 
rats previously treated with HAL and OLZ, and retested 
under the same dose of drugs after their avoidances re-
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An Investigation of the Behavioral Mechanisms of Antipsychotic 
Action Using a Drug-Drug Conditioning Paradigm
Ming Li (mli2@unl.edu), Wei He and Alexa Mead
Antipsychotic drugs at noncataleptic doses selectively suppress conditioned avoidance response in rats. In our previous 
study, we had used a two-way active avoidance response paradigm to show that the antipsychotic-induced interoceptive 
state is one of the mechanisms underlying the avoidance-disruptive effect of antipsychotics. In this study, we sought to 
further examine this mechanism using a novel drug-drug conditioning procedure. We made use of the fact that both 
the typical neuroleptic haloperidol and the atypical neuroleptic olanzapine disrupt conditioned avoidance responding, 
whereas chlordiazepoxide (an anxiolytic) does not. We reasoned that if the antipsychotic interoceptive state is important 
in causing a disruption on avoidance responding (an index of antipsychotic efficacy), pairing chlordiazepoxide (a cueing 
drug conditional stimulus) with haloperidol or olanzapine (a cued drug unconditional stimulus) should engender 
chlordiazepoxide to exhibit this property and behave like an antipsychotic drug. Chlordiazepoxide exhibited an acquired 
antipsychotic-like property in disrupting avoidance responding after being repeatedly paired with haloperidol, but not 
with olanzapine. In contrast, it significantly attenuated the antiavoidance efficacy of olanzapine but not haloperidol 
after being repeatedly paired with these drugs. This study suggests that the haloperidol-induced interoceptive drug 
state is directly involved in its antiavoidance action, and chlordiazepoxide may attenuate the antiavoidance efficacy of 
antipsychotics (especially olanzapine). To the extent that the antiavoidance effect predicts clinical effects of antipsychotic 
treatment, this study suggests that the antipsychotic-induced interoceptive drug state may be an important behavioral 
mechanism mediating the clinical effects of antipsychotic treatments.
Keywords: antipsychotic drugs, chlordiazepoxide, conditioned avoidance response, drug-drug conditioning, polypharmacy, psychotherapeutic 
drug-drug interaction, rat, schizophrenia 
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Introduction
Antipsychotic drugs (APDs) are effective in the treat-
ment of positive symptoms of schizophrenia (Lieberman 
et al., 2005). Research over the years has shown that ac-
tions at various receptor sites, notably dopamine D2, sero-
tonin 5-HT2A, and 5-HT1A receptors, are critically impor-
tant for the therapeutic effect of both typical and atypical 
drugs (Seeman, 2000; Kapur and Mamo, 2003; Richtand 
et al., 2007). It is still not well understood how this action 
at the neurobiological level translates into symptom im-
provement. This situation is peculiar given the fact that 
schizophrenia is a cluster of psychological symptoms, and 
the diagnosis and symptom improvement all manifests at 
the psychological level. The neurobiological level of ex-
planations of antipsychotic action alone is clearly insuffi-
cient to account for the clinical effect of antipsychotic ac-
tion (Miller, 1987; Kapur, 2003). To understand fully how 
antipsychotics work, a detailed understanding of the be-
havioral mechanisms of antipsychotic action is needed.
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per cage, in 48.3 × 6.7 × 20.3 cm transparent polycarbonate 
cages under 12-h light/dark conditions (light on between 
6:30 am and 6:30 pm). Room temperature was maintained 
at 21 ± 11°C with a relative humidity of 55-60%. Food and 
water was freely available. Animals were allowed at least 
1 week of habituation to the animal facility before being 
used in experiments. All procedures were approved by 
the Institutional Animal Care and Use Committee at the 
University of Nebraska-Lincoln.
Avoidance conditioning apparatus
Six identical two-way shuttle boxes, custom designed 
and manufactured by Med Associates (St. Albans, Ver-
mont, USA), were used. Each box was housed in a venti-
lated, sound-insulated isolation cubicle (96.52 cm wide × 
35.56 cm deep × 63.5 cm high). Each box was 64 cm long, 
30 cm high (from grid floor) and 24 cm wide, and divided 
into two equal-sized compartments by a white polyvinyl 
chloride partition with an arch-style doorway (15 cm high 
× 9 cm wide at base). An aluminum hurdle (4 cm high) 
was placed between the two compartments, so the rats 
had to jump from one compartment to enter the other. 
The grid floor consisted of 40 stainless-steel rods, spaced 
1.6 cm apart center to center, through which a scram-
bled footshock (0.8 mA) was delivered by a constant cur-
rent shock generator (Model ENV-410B) and scrambler 
(Model ENV-412). The location of the rat and motor activ-
ity were detected by a set of 16 photobeams (ENV-256-8P) 
affixed at the bottom of the box (3.5 cm above the grid 
floor). A speaker (ENV 224AMX) mounted on the ceiling 
of the cubicle, centered above the shuttle box, was used 
to provide a CS (76 dB white noise). All the training and 
testing procedures were controlled by Med Associates 
programs running on a computer. Background noise (ap-
proximately 74 dB) was provided by a ventilation fan af-
fixed at the top corner of each isolation cubicle. 
Drugs
The injection solutions of HAL (5 mg/ml ampoules, Sa-
bex Inc., Boucheville, Quebec, Canada) and CDP (Sigma-
Aldrich, St Louis, Missouri, USA) were obtained by mix-
ing drugs with sterile water. OLZ (Toronto Research 
Chemical Inc., Canada) was dissolved in 1.5% glacial ace-
tic acid in distilled water. HAL and OLZ were adminis-
tered s.c., whereas CDP was administered intraperitone-
ally. The doses of HAL (0.05 mg/kg) and OLZ (1.0 mg/
kg) and their injection route were chosen based on (i) our 
previous work showing that at the chosen doses, HAL 
and OLZ injected s.c. produce a comparable progressive 
across-session decline in avoidance responding (Li et al., 
2007); and (ii) rat brain D2 receptor occupancy data show-
ing that both drugs give rise to clinically comparable lev-
els of D2 occupancy (65-80%) (Kapur et al., 2003). The 
choice of CDP dose (10 mg/kg) and its route of injection 
was based on the findings showing that (i) CDP (10 mg/
kg) is ineffective in disrupting avoidance responding (Li 
et al., 2004, 2007); (ii) CDP at this dose is effective in sev-
eral aversively conditioned paradigms, such as Pavlov-
covered to the predrug level, showed fewer avoidances 
than when they were first tested (Mead and Li, in press). 
This finding indicates that the interoceptive drug state in-
duced by HAL may also play a role in causing a progres-
sive decline in avoidance across sessions. On the basis of 
these findings, we proposed that antipsychotics may sup-
press avoidance responding through a dual action: (i) de-
creasing the motivational salience of stimuli; (ii) provid-
ing an interoceptive drug cue that allows the decreased 
salience of stimuli to be maintained over time.
In contrast to the well-documented salience attenuation 
effect of antipsychotics (Fouriezos et al., 1978; Berridge 
and Robinson, 1998; Dickinson et al., 2000; Wise, 2004; 
Colpaert et al., 2007), the notion that the drug-induced in-
teroceptive state(s) may be involved in the antipsychotic 
effects is relatively new, although preclinical studies such 
as those based on drug discrimination and state-depen-
dent learning have long recognized the distinct drug states 
induced by typical and atypical antipsychotics (Overton, 
1979; Goudie et al., 1998; Porter et al., 2000b; Porter et al., 
2005). The primary goal of this study was thus to exam-
ine this mechanism further, using a novel drug-drug con-
ditioning paradigm in the CAR model. In this study, we 
utilized the fact that both HAL (typical APD) and OLZ 
(atypical APD) disrupt conditioned avoidance respond-
ing, whereas chlordiazepoxide (CDP) does not (Sanger, 
1985; Li et al., 2004, 2007). If the antipsychotic-induced 
state is directly involved and critically important in caus-
ing a disruption on avoidance responding, pairing CDP 
with HAL or OLZ through a drug-drug conditioning pro-
cedure (Revusky et al., 1989; Taukulis, 1996) should alter 
the intrinsic property of CDP and engender it to show a 
disruptive effect on avoidance responding. In Pavlovian 
terminology, the CDP was considered a CS drug, which 
signals to an organism that the effects of HAL or OLZ 
(US) are imminent. Any avoidance-disruptive effect ex-
hibited by CDP after repeated pairing with HAL or OLZ 
would support the notion that antipsychotic-induced in-
teroceptive state is ‘directly’ involved in the antipsychotic 
effect.
As psychotic fear and anxiety disturbances are seen at 
a relatively high frequency in patients with schizophre-
nia (Siris, 1994), anxiolytic drugs are frequently combined 
with antipsychotics in schizophrenic patients (ZumBrun-
nen and Jann, 1998). This practice of psychotropic polyp-
harmacy has raised some concerns regarding the possible 
adverse effects of drug-drug interactions (Sandson et al., 
2005). This study also allowed us to examine how the re-
peated pairings of CDP with HAL and OLZ might alter 
the intrinsic drug efficacy of HAL and OLZ.
Methods
Subjects
Male Sprague-Dawley rats (226-250 g upon arrival, 
Charles River, Portage, Michigan, USA) were housed two 
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pose of giving rats the drug treatments on day 2 and not 
testing them was to ensure that every rat received the 
same drug treatment (all rats had CDP, HAL, and VEH), 
although in different contexts (e.g. home cage vs. CAR 
boxes) and with different drug injection intervals (15 min 
vs. 24 h), so that the specific drug-drug conditioning ef-
fect on avoidance behavior could be assessed. On day 3, 
all rats were untreated and unhandled. This 3-day drug 
conditioning cycle repeated for seven times over a 21-
day period, after which all rats were re-trained drug-free 
in two consecutive sessions to bring back a high level of 
avoidance responding.
Drug-testing phase
The drug-testing phase started 24 h after the last retrain-
ing session. Rats were first injected with CDP (10.0 mg/
kg, i.p.) and tested 75 min later. The next day, rats were 
retrained drug-free, and 1 day later, tested again under 
HAL [0.05 mg/kg, subcutaneously (s.c.), – 60 min]. For 
both drug tests, the same conditioned avoidance proce-
dure was used except that only the CS was presented in 
the 30 trials. No shock US was ever presented. The fol-
lowing figure illustrates the general experimental proce-
dure (Figure 1).
Experiment 2: effects of repeated chlordiazepoxide and 
olanzapine pairing on avoidance responding to chlordi-
azepoxide and olanzapine
This experiment was identical to experiment 1 except 
that HAL was replaced by OLZ. Forty-two rats were used, 
of which 30 reached learning criterion. They were then 
randomly assigned to one of the following four groups: 
CDP + VEH (n = 6), VEH + OLZ (n = 8), CDP+OLZ (n = 9), 
and VEH + VEH (n = 7), and were subjected to the seven 
sessions of drug conditioning and two sessions of drug 
testing (the CDP test followed by the OLZ test).
Experiment 3: reexamining the effects of repeated 
chlordiazepoxide and haloperidol pairing on avoidance 
responding to chlordiazepoxide and haloperidol
As the CDP + HAL (experiment 1) and CDP + OLZ 
pairing (experiment 2) produced different results, we re-
examined the effects of repeated CDP and HAL pairing 
on avoidance responding to CDP and HAL. Twenty rats 
that had experienced the same white noise and footshock 
in a Pavlovian fear-conditioning paradigm were used. It 
should be noted that none of the rats were ever exposed 
to any drug before this experiment and that there was at 
least a 2-week window between the previous experiment 
and this one (unpublished experiment). The basic proce-
dure was the same as the one used in the previous two 
experiments. First, all rats were trained in 10 avoidance 
conditioning sessions. At the end of the training Figure 
2 phase, 15 rats reached the learning criterion and were 
randomly assigned to two groups: CDP + HAL (n = 8) 
and VEH+HAL (n = 7). They were then subjected to the 
seven sessions of drug conditioning and two sessions of 
drug testing (the CDP test followed by the HAL test).
ian fear conditioning and passive avoidance responding 
(Klint, 1991; Joordens et al., 1998); and (iii) at this dose, CDP 
produces a powerful internal drug cue (Colpaert, 1986).
Experiment 1: effects of repeated chlordiazepoxide and 
haloperidol pairing on avoidance responding to chlordi-
azepoxide and haloperidol
The experiment comprised of the following three 
phases: avoidance training, drug–drug conditioning, and 
drug testing.
Avoidance training phase
Forty-two rats were first handled and habituated to the 
avoidance conditioning apparatus for 2 days (30 min/
day), and then trained for 10 consecutive days to acquire 
robust conditioned avoidance responding (> 70% avoid-
ance trials). Each training session consisted of 30 discrete 
trials. Every trial was started by presenting white noise 
(CS, 76 dB) for 10 s, followed by a continuous footshock 
(US, 0.8 mA, maximum 5 s) on the grid floor. If a subject 
moved from one compartment into the other within the 
10 s of CS presentation, the shock was prevented, and this 
shuttling response was recorded as ‘avoidance’ (a two-
way avoidance). If the rat remained in the same compart-
ment for more than 10 s and made a crossing upon receiv-
ing the footshock, this response was recorded as ‘escape.’ 
If the rat did not respond during the entire 5 s presen-
tation of the shock, the trial was terminated and ‘escape 
failure’ was recorded. Intertrial intervals varied randomly 
between 30 and 60 s.
Drug conditioning phase
At the end of the training phase, rats (n = 32) that had 
reached the training criterion (≥ 70% avoidance in each 
of the last two sessions) were used in the drug condition-
ing phase. They were randomly assigned to one of four 
groups. On day 1, each group was given a double injec-
tion of one of the following combinations: CDP + vehicle 
(VEH) (n = 8), VEH + HAL (n = 7), CDP+HAL (n =7), and 
VEH +VEH (n = 10). The first injection (CDP 10.0 mg/
kg, or sterile water, 1.0 ml/kg, i.p.) was given 15 min be-
fore the second injection (HAL 0.05 mg/kg, or sterile wa-
ter, 1.0 ml/kg, s.c.). One hour after the second injection, 
rats were placed in the avoidance conditioning boxes 
and tested. This time interval between CDP and HAL (15 
min) was determined so that there was sufficient time for 
the drug effects of HAL and CDP to overlap and pro-
duce a robust drug-drug conditioning effect, given the 
half-life of CDP at 4-6 h (Koechlin et al., 1965) and HAL 
at about 1.5 h (Cheng and Paalzow, 1992). A similar kind 
of drug-drug conditioning arrangement had been used 
by Taukulis and Brake (1989). On day 2, rats in the CDP 
+ VEH, VEH + HAL, and CDP + HAL groups received 
a single injection of HAL, CDP, and VEH, respectively, 
whereas the Behavioral mechanisms of antipsychotic ac-
tion Li et al. 3 VEH + VEH group received a double in-
jection of CDP and HAL separated by 15 min. Immedi-
ately after the injections, rats were returned to their home 
cages. No avoidance test was done on this day. The pur-
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drug conditioning sessions and two drug-free retraining 
sessions. The two HAL groups (e.g. the CDP + HAL and 
VEH + HAL) showed a progressive across-session de-
crease in avoidance responding under drug and a quick 
Statistics
The main dependent variable was the number of avoid-
ance responses (expressed as mean ± SEM). Data from 
the drug-drug conditioning phase were first analyzed us-
ing a repeated-measures analysis of variance (ANOVA) 
with treatments (i.e. four groups) as a between-subjects 
CDP+VEH (n = 8)factor and the test sessions (i.e. seven 
drug sessions) CDP + HAL (n = 7) VEH + VEH (n = 10)
VEH + HAL (n = 7) as a within-subjects factor, followed 
by post-hoc Tukey’s honestly significant difference test 
to detect the group differences. If a significant group dif-
ference was detected, one-way ANOVAs were then used 
to specify the difference for each drug session. Data from 
the drug-testing phase were analyzed separately using 
one-way ANOVAs, followed by Tukey’s test. A conven-
tional two-tailed level of significance at the 5% level was 
required. 
Results
Experiment 1: effects of repeated chlordiazepoxide and 
haloperidol pairing on avoidance responding to chlordi-
azepoxide and haloperidol
Figure 2 shows the number of avoidance responses 
made by the rats in the four groups during the seven 
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different from the CDP + VEH and VEH + VEH groups 
(all P values < 0.001). Interestingly, the CDP + HAL group 
also differed significantly from the VEH + HAL group (P 
= 0.045). Individual one-way ANOVA revealed that on 
the first two drug conditioning days, the CDP + HAL rats 
displayed higher numbers of avoidance responses than 
the rats in the VEH + HAL group (day 1: P < 0.05; day 
2: P < 0.05), indicating that CDP may have attenuated 
the HAL effect, at least at the early stage of paired drug 
treatment. This attenuation was also reflected in the two
recovery when the treatment was stopped. The other two 
groups (e.g. the CDP + VEH and VEH + VEH) maintained 
a high level of avoidance responding throughout the en-
tire drug conditioning phase. For the seven drug condi-
tioning sessions, a two-way ANOVA (‘treatments’ × ‘ses-
sions’) showed a significant effect of ‘treatments’ [F(3,28) = 
322.85, P < 0.001], ‘sessions’ [F(6,168) = 28.04, P < 0.001], and 
a significant ‘treatments’ × ‘sessions’ interaction [F(18,168) = 
15.173, P <0.001]. Post-hoc Tukey tests revealed that the 
CDP + HAL and VEH + HAL groups were significantly
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avoidance responding under drug and a quick recovery 
when OLZ treatment was stopped. The other two groups 
(e.g. the CDP + VEH and VEH + VEH) maintained a high 
level of avoidance responding throughout the entire drug 
conditioning phase. For the seven drug conditioning 
sessions, a two-way ANOVA (‘treatments’ × ‘sessions’) 
showed a significant effect of ‘treatments’ [F(3,26) = 69.05, P 
< 0.001], ‘sessions’ [F(6,156) = 6.91, P < 0.001], and a signifi-
cant ‘treatments’ × ‘sessions’ interaction [F(18,156) = 4.29, P 
< 0.001]. Post-hoc two-group comparisons revealed that 
both OLZ-treated groups were significantly different 
from the other two groups (all P values < 0.001), indicat-
ing a potentiated inhibitory effect of repeated OLZ treat-
ment on avoidance responding. This potentiated effect 
appears to be attenuated to an extent by CDP, as the CDP 
+ OLZ group showed less of a decrease than the VEH + 
OLZ group. Independent samples t-tests on each drug 
conditioning day revealed that there were significant dif-
ferences between the two groups on day 4(P < 0.001), day 
5 (P < 0.02), and day 6 (P < 0.05).
Figure 5a shows the number of avoidance responses dur-
ing the CDP test. All four groups showed a comparably 
high level of avoidance responding. One-way ANOVA 
did not show any significant group difference [F(3,26) = 1.97, 
NS], suggesting that CDP given alone or in combination 
with OLZ did not change its action on avoidance behav-
ior. After a retraining session [pre-OLZ session: no group 
difference was detected, F(3,26) = 2.77, P = 0.061, Figure 5b],
subsequent retraining sessions, as the CDP + HAL group 
reinstated avoidance responding much faster than the 
VEH + HAL group (CDP + HAL vs. VEH + HAL: day 1: 
P < 0.01; day 2: P < 0.05). Furthermore, the CDP + HAL 
group showed no significant difference when compared 
with the CDP + VEH and VEH + VEH groups (all P val-
ues > 0.09), whereas the VEH + HAL did (all P values < 
0.01).
Figure 3a shows the number of avoidance responses 
during the CDP test. Both the CDP + VEH and VEH + 
VEH groups exhibited a high level of avoidance respond-
ing (the average was 26.4 and 25.7 avoidances, respec-
tively), as did the VEH + HAL group (mean number: 
19.4), even though there was no shock (only white noise) 
present during this test. This finding was consistent with 
the data from the drug conditioning phase, showing that 
CDP itself has no effect on avoidance responding. In con-
trast, the CDP + HAL group exhibited the lowest avoid-
ance responses (8.1). One-way ANOVA revealed that the 
CDP + HAL group was significantly different from the 
other three groups (all P values < 0.025), strongly suggest-
ing that CDP produced a significant inhibition of avoid-
ance responding. In other words, CDP ‘acquires’ a HAL-
like property (e.g. disrupting avoidance responding) after 
being repeatedly paired with HAL. Prior CDP + HAL 
pairing in the absence of avoidance testing (e.g. the VEH 
+ VEH group) did not change its property.
After a retraining session [pre-HAL session: no group 
difference was detected, F(3,28) = 2.16, P = 0.12, Figure 3b], 
all rats were tested for their avoidance responses under 
HAL in a CS-only session (Figure 3b). In comparison 
with the pre-HAL session, avoidance responding was ap-
parently lower in all groups. A 4 × 2 repeated-measures 
ANOVA (‘treatment’ × ‘sessions’) showed a significant 
effect of ‘treatment’ [F(3,28) = 5.34, P < 0.005], ‘sessions’ 
[F(1,28) = 640.48, P < 0.001], and a significant ‘treatment’ 
× ‘sessions’ interaction [F(3,28) = 3.45, P < 0.05]. One-way 
ANOVA focusing on the HAL test session revealed no 
significant group difference except between the VEH + 
HAL and VEH + VEH groups (P < 0.005), indicating a 
strong HAL experience effect consistent with our previ-
ous finding (Li et al., 2007). More importantly, no signif-
icant group difference was detected between the VEH + 
HAL and CDP + HAL groups, indicating that the efficacy 
of HAL had not been altered even after being repeatedly 
paired with CDP.
Experiment 2: effects of repeated chlordiazepoxide and 
olanzapine pairing on avoidance responding to chlordi-
azepoxide and olanzapine
Figure 4 shows the number of avoidance responses 
made by the rats in the four groups during the seven 
drug conditioning sessions and two drug-free retraining 
sessions. Similar to what was seen in experiment 1, the 
two OLZ-treated groups (e.g. the CDP + OLZ and VEH 
+ OLZ) showed a progressive across-session decrease in 
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treatment (e.g. CDP and OLZ pairing), this result suggests 
that OLZ might lose its antipsychotic action after being 
repeatedly paired with CDP. 
Experiment 3: reexamining the effects of repeated 
chlordiazepoxide and haloperidol pairing on avoidance 
responding to chlordiazepoxide and haloperidol
Figure 6 shows the number of avoidance responses 
during the seven drug conditioning sessions and two 
drug-free retraining sessions. Both groups showed a 
progressive across-session decrease in avoidance re-
sponding under drug, and a recovery when HAL was 
stopped. For the seven drug conditioning sessions, a 
two-way ANOVA (‘treatments’ × ‘sessions’) showed a
all rats were tested for their avoidance responses under 
OLZ in a CS-only session. In comparison with the pre-
OLZ session, avoidance responses were significantly de-
creased by OLZ, especially in the CDP + VEH and VEH 
+ OLZ groups. A 4 × 2 two-way ANOVA (‘treatment’ × 
‘sessions’) showed a significant effect of ‘treatment’ [F(3,26) 
= 8.11, P < 0.001], ‘sessions’ [F(1,26) = 149.25, P < 0.001], and 
a significant ‘treatment’ × ‘sessions’ interaction [F(3,26) = 
5.04, P < 0.01]. Post-hoc two-group comparisons revealed 
that the CDP + OLZ and VEH + VEH groups were signif-
icantly different from the CDP + VEH and VEH + OLZ 
groups (all P values < 0.05). The CDP + VEH group did 
not differ from the VEH + OLZ group. As the CDP + 
OLZ and VEH + VEH groups all received a double drug 
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psychotic-induced interoceptive state in the therapeu-
tic effects of antipsychotic treatment. Results from ex-
periments 1 and 3 suggest that the HAL-induced intero-
ceptive state may be involved in its disruptive effect on 
avoidance responding, as evidenced by the finding show-
ing that CDP + HAL pairing produced an anti-avoid-
ance (e.g. antipsychotic-like) drug activity in CDP. This 
‘acquired’ HAL activity of CDP is attributed to specific 
drug-drug conditioning with CDP functioning as the 
drug CS, and HAL as the drug US (Taukulis and Brake, 
1989). It is not simply because of pharmacological effects 
of the drugs, as no such effect was found in two control 
groups (the CDP + VEH and VEH + HAL), even though 
they received the same numbers of CDP and HAL injec-
tions separated by 24 h. We also showed that, to induce 
the anti-avoidance effect in CDP, CDP + HAL pairing had 
to occur within the context of avoidance testing. The same 
pairing in the home cage (the VEH + VEH group) did not 
change the drug activity of CDP, indicating an important 
significant effect of ‘sessions’ [F(6,78) = 6.36, P < 0.001], but 
not ‘treatments’ [F(1,13) = 0.048, NS], or ‘treatments’ × ‘ses-
sions’ interaction [F(6,78) = 0.806, NS]. During the two sub-
sequent retraining sessions, it appeared that the CDP + 
HAL group reinstated avoidance behavior much faster 
than the VEH + HAL group and had higher mean num-
bers of avoidances on both days. This group difference 
was significant on the first day (P < 0.05), but failed to 
reach a significant level on the second day.
The pattern was reversed on the CDP test (Figure 7a). 
The CDP + HAL group showed many fewer avoidances 
than the VEH + HAL group, and this difference was sta-
tistically significant [t(13) = 3.00, P < 0.01]. This result con-
firmed the finding from experiment 1 and supported the 
notion that CDP might ‘acquire’ an antipsychotic prop-
erty after being repeatedly paired with HAL.
After a retraining session [pre-HAL session: no group 
difference was detected, t(13) = – 1.82, NS, Figure 7b], all 
rats were tested for their avoidance responses under HAL 
in a CS-only session (Figure 7b). As can be seen in Figure 
7b, in comparison with the pre-HAL session, avoidance 
responding was significantly decreased by HAL [F(1,13) = 
173.26, P < 0.001]. There was no significant difference be-
tween groups [F(1,13) = 2.49, NS], indicating that the effi-
cacy of HAL was not altered even if it had been repeat-
edly paired with CDP. 
Discussion
In the three experiments, we used a novel drug–drug 
conditioning paradigm and examined the role of anti-
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thioridazine substituted for OLZ in producing OLZ-ap-
propriate responding in rats, as did the muscarinic cho-
linergic antagonist scopolamine and the 5-HT2A/2C sero-
tonergic antagonist ritanserin. This finding suggests that 
the antagonism of either dopamine D2 receptors, mus-
carinic receptors, or 5-HT2A/2C receptors is sufficient to 
mimic the OLZ-induced interoceptive state. Colpaert et 
al. (2007) used a two-lever, food-rewarded drug discrim-
ination paradigm and found that HAL was more effica-
cious than OLZ in inducing ‘win-shift’ response pattern, 
possibly because of its strong D2 receptor antagonism. As 
the ‘antipsychotic’ action, as well as the antiavoidance 
effect is thought to be mediated by antagonism against 
D2 receptors (Wadenberg et al., 2001; Seeman, 2006), the 
compound cue mediated by multiple receptor actions of 
OLZ is apparently less effective in bestowing an antipsy-
chotic property to CDP than the single cue mediated by 
D2 blockade by HAL. This is because other discriminative 
cues within this compound cue may obscure the ‘antip-
sychotic’ cue. Within the same line of reasoning, it is also 
possible that the differential effects of CDP + HAL and 
CDP + OLZ pairing is because of the differences between 
the dopamine D2 receptor bindings of HAL and OLZ. The 
binding affinity of HAL at D2 receptors is six to seven times 
greater than that of OLZ (Richelson and Souder, 2000), so 
although they may share a similar molecular mechanism 
in blocking D2 receptors, they are not equally efficacious 
at this site. This distinct molecular binding profile of OLZ 
opens up the possibility that the discrepant findings rep-
resent a pharmacological effect between CDP and OLZ 
that was not present between CDP and HAL.
Another unexpected finding is that repeated concur-
rent CDP and OLZ treatment attenuated the antiavoid-
ance effect of OLZ (Figure 5b), but not HAL (Figure 3b 
interaction between drug treatment and targeted behav-
ior as well as the direct involvement of HAL-induced 
drug state in the disruption of avoidance responding.
Unexpectedly, we did not find the same effect with CDP 
+ OLZ pairing from experiment 2. CDP + OLZ pairing 
did not change the drug activity of CDP on avoidance re-
sponding. However, it did change the efficacy of OLZ, 
making it less effective in disrupting avoidance behavior 
when it was tested alone. This effect is because of drug-
drug conditioning, as the control groups without condi-
tioning (the CDP + VEH and VEH + OLZ) did not show 
such an effect. In addition, the contexts within which the 
CDP + OLZ conditioning occurred were not critical be-
cause even the drug pairing in the home cage achieved a 
similar effect (Figure 5b). Overall, the present findings re-
veal an interesting ‘double dissociation’ between the ef-
fect of CDP pairing with typical antipsychotic HAL and 
atypical OLZ. CDP + HAL pairing changed the drug ac-
tivity of CDP, but did not change that of HAL. CDP exhib-
ited an acquired antiavoidance effect after being repeat-
edly paired with HAL. In contrast, CDP + OLZ pairing 
changed the drug activity of OLZ, but not that of CDP. 
OLZ became less effective in disrupting avoidance behav-
ior after repeated pairing.
This study provides additional evidence showing that 
the HAL-induced interoceptive state is related to its anti-
avoidance effect, a finding consistent with our previous 
work (Li et al., 2007; Mead and Li, in press). The differ-
ential effect of CDP + HAL and CDP + OLZ pairing is 
surprising, given the fact that both HAL and OLZ are 
equally efficacious in the treatment of psychosis (Lieber-
man et al., 2003) and share a similar molecular mecha-
nism in blocking dopamine D2 receptors (Kapur and See-
man, 2000). At the chosen doses, they also produced a 
comparable level of avoidance disrupting effect over the 
seven drug conditioning days (Figs 2 and 4). One possi-
ble explanation for the differential effect of CDP + HAL 
and CDP + OLZ pairing is that HAL and OLZ may in-
duce different interoceptive states that are differently in-
fluenced by CDP. Pharmacologically, HAL is primarily a 
D2 receptor antagonist (Kapur et al., 1996), and it binds 
‘tightly’ to the D2 receptor and dissociates slowly (Kapur 
and Seeman, 2001), whereas OLZ has a moderate antag-
onist effect on the D2 receptor but a high antagonist ef-
fect on the 5-HT2A serotoninergic, α1 adrenergic, m1 mus-
carinic, and H1 histaminic receptors (Bymaster et al., 1999; 
Miyamoto et al., 2005) (Table 1). It is possible that the 
OLZ state is a compound cue that is mediated by its an-
tagonism against multiple receptors (e.g. D2, 5-HT2A, α1, 
m1 and H1, etc.), whereas the HAL state is a single cue 
that is primarily mediated by antagonism against D2 re-
ceptors. Drug discrimination studies seem to support 
this notion (Goudie and Taylor, 1998; Porter et al., 2000a; 
Cole et al., 2007; Goudie et al., 2007). Using a two-lever 
drug discrimination paradigm, Porter et al. (2000a) found 
that the dopamine D2 antagonists chlorpromazine and
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tioning. In many drug conditioning studies, the drug con-
ditioning effect is often indexed by some change in one 
or more of the properties of the CS drug (Taukulis, 1996). 
For example, in a series of studies on the diazepam-HAL 
or diazepam-chlorpromazine conditioning (Taukulis and 
Brake, 1989; Taukulis et al., 1992), the drug conditioning 
was evidenced by the changed drug properties of diaz-
epam, such as enhanced hypothermia, diminished mus-
cle relaxation, and enhanced anxiolytic effect. As rightly 
pointed out by Taukulis (1996), this approach occasionally 
posits a challenge in the explanation for the drug condi-
tioning phenomenon, because the specific unconditional 
effects of the ‘signaled’ drug (drug US) have not always 
been specified in advance. In this study, the condition-
ing effect was seen in the newly ‘acquired’ antipsychotic 
property in CDP, which is not an intrinsic drug property 
of CDP, and can only be attributed to the unconditioned 
effect of HAL. This approach provides an unequivocal 
demonstration of the drug-drug conditioning effect.
In summary, our results show that the HAL-induced in-
teroceptive state is an important behavioral mechanism 
responsible for the maintenance of its antiavoidance ef-
fect and possibly antipsychotic effect over time. Concur-
rent use of CPD with antipsychotics, especially with OLZ, 
may cause a long-term attenuation of the antiavoidance 
effect of OLZ through a drug-drug interaction mecha-
nism. The model introduced in this study may be useful 
in delineating behavioral mechanisms of antipsychotic 
action and assessing polypharmacy involving drug-drug 
conditioning in the treatment of schizophrenia. 
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